Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Articles|April 1, 2018

BioPharm International

  • BioPharm International-04-01-2018
  • Volume 31
  • Issue 4

Automated Benchtop Pipette

The Concentrating Pipette Select from InnovaPrep is a small automated benchtop instrument that can concentrate contaminates from large volumes of liquids for improved detection.

The Concentrating Pipette Select from InnovaPrep is a small automated benchtop instrument that can concentrate contaminates from large volumes of liquids for improved detection. The instrument allows for contamination screening of liquid samples up to 5L and lets users choose from six versions of interchangeable, high-flow filtered pipette tips that feature different specifications to concentrate proteins, viruses, DNA, bacteria, whole cells, fungal spores, or other particles. Recovered particles are delivered in seconds and ready for analysis using user method of choice, according to the company.

Applications for the pipette include biological and particulate contamination monitoring in the environment, as well as monitoring the integrity of various ingredients including water, intermediate products such as cell culture media, and finished products including parenteral fluids and compounded drugs.

According to InnovaPrep, when used as a front-end to rapid molecular methods for quality assurance/quality control monitoring, the instrument allows for sample-to-answer within a single shift, improving detection of trace contamination. 

InnovaPrep


Related to this article

The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron and Alnylam’s cemdisiran (Livsayis) as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.
The BioPharm Brief: A First for Streamlined Biosimilar Approval, a Head-to-Head Bispecific Trial in Wet AMD, and In Vivo KIR-CAR T
Biocon’s pertuzumab biosimilar Pebrilzo becomes the first biosimilar approved under EMA’s tailored clinical approach, Visara doses the first patient in a phase 2b trial comparing its VEGF-A/ANG-2 bispecific VIS-101 with aflibercept in wet AMD, and Verismo Therapeutics licenses Stanford’s PACK-IT technology for in vivo KIR-CAR T therapies.